Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]
对“肺免疫肿瘤预后评分（LIPS-3）：接受一线帕博利珠单抗治疗的PD-L1 ≥ 50%晚期非小细胞肺癌患者的预后分类”的更正：[ESMO Open 第6卷，第2期，2021年4月，100078]
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100137
Banna, G L; Cortellini, A; Cortinovis, D L; Tiseo, M; Aerts, J G J V; Barbieri, F; Giusti, R; Bria, E; Grossi, F; Pizzutilo, P; Berardi, R; Morabito, A; Genova, C; Mazzoni, F; Di Noia, V; Signorelli, D; Gelibter, A; Macerelli, M; Rastelli, F; Chiari, R; Rocco, D; Gori, S; De Tursi, M; Di Marino, P; Mansueto, G; Zoratto, F; Filetti, M; Montrone, M; Citarella, F; Marco, R; Cantini, L; Nigro, O; D'Argento, E; Buti, S; Minuti, G; Landi, L; Guaitoli, G; Lo Russo, G; De Toma, A; Donisi, C; Friedlaender, A; De Giglio, A; Metro, G; Porzio, G; Ficorella, C; Addeo, A
肺癌
SMO
肿瘤
肿瘤免疫
PD-L1
细胞生物学
免疫/内分泌
